The present invention relates to medical pumps for delivering medicament to a patient and, more specifically, to user-wearable infusion pumps for delivering medicament such as insulin to a patient.
There are many applications in academic, industrial, and medical fields that benefit from devices and methods that are capable of accurately and controllably delivering fluids, such as liquids and gases, that have a beneficial effect when administered in known and controlled quantities. Such devices and methods can be particularly useful in the medical field where treatments for many patients include the administration of a known amount of a substance at predetermined intervals.
One category of devices for delivering such fluids is that of pumps that have been developed for the administration of insulin and other medicaments for those suffering from both Type 1 and Type 2 diabetes. Some pumps configured as portable infusion devices can provide continuous subcutaneous medicament injection and/or infusion therapy for the treatment of diabetes. Such therapy may include, e.g., the regular and/or continuous injection or infusion of insulin into the skin of a person suffering from diabetes and offer an alternative to multiple daily injections of insulin by an insulin syringe or an insulin pen. Such pumps can be ambulatory/portable infusion pumps that are worn by the user and may use replaceable cartridges. Examples of such pumps and various features that can be associated with such pumps include those disclosed in U.S. Patent Application Publication No. 2013/0053816; U.S. Pat. Nos. 8,573,027; 8,986,253; U.S. Patent Application Publication No. 2013/0324928; U.S. Patent Application Publication No. 2013/0331790; U.S. Pat. No. 8,287,495; U.S. Patent Publication No. 2017/0049957; and U.S. Patent Publication No. 2016/0339172, each of which is hereby incorporated herein by reference in its entirety.
One common type of ambulatory infusion pump utilizes an electromagnetic motor to rotate a lead screw that drives a syringe to cause medicament to be delivered from a medicament reservoir in the pump to a patient. Most such systems incorporate a gear reduction system to decrease the speed generated by the motor in order to increase the torque on the lead screw to a sufficient level to cause the medicament to be dispensed. Such systems generally employ a force sensor for detecting and monitoring pressure conditions in the syringe cartridge. However, this additional sensor requires additional space and electronics and represents an additional possible failure point in a complex electromechanical system.
Another type of ambulatory infusion pump that has been developed utilizes piezoelectric elements to rotate a lead screw and drive a syringe that causes medicament to be delivered. One such pump, further details of which can be found in U.S. Patent Publication No. 2017/0049957 assigned to the assignee of the present application, does not requires a gear reduction system in order to drive the syringe. Therefore, this type of pump requires fewer parts and can be made smaller than pumps that utilize gear reduction systems. This type of pump can also employ an encoder system. The encoder system may in one example utilize an optical encoder integrated circuit that monitors markings configured radially around an outer surface of a cylindrical drive element in order to monitor a rotational position of the drive element.
Disclosed herein are systems and methods for monitoring performance of an ambulatory infusion pump. An ambulatory infusion pump can include a reservoir configured to contain a medicament including a plunger at a proximal end of the reservoir and an outlet port at a distal end of the reservoir. A motor can be configured to cause linear motion of a pushrod to contact and move the plunger to cause medicament to flow from the reservoir out of the outlet port to a patient. An optical encoder can be employed to monitor a linear position of the pushrod. In addition, the optical encoder can be employed to monitor additional system conditions and/or a secondary encoder can be employed to monitor the performance of the optical encoder.
In embodiments, systems and methods for monitoring and detecting pressure conditions in a syringe-based infusion pump without the use of a separate force sensor are disclosed herein. In an infusion pump that employs a piezoelectric motor to rotate a lead screw without a gear reduction system and that utilizes an encoder for monitoring a position of the lead screw, the encoder can further be utilized to detect pressure conditions in the system. As pressure in the system increases, the torque required to rotate the lead screw increases which causes the time it takes for a rotational displacement of a give size to occur to be longer. By monitoring the time required for a given rotational displacement to occur, it is possible to detect high or low pressure conditions in the cartridge.
In embodiments, systems and methods for monitoring performance of a primary encoder used to provide feedback regarding operation of a user-wearable infusion pump by monitoring markings on a rotationally driven element of the pump are disclosed herein. Such a primary encoder operates relative to the markings and in some embodiments is powered on and off within, e.g., a single revolution of the drive element to, e.g., reduce power consumption. As such, the encoder may drift slightly when power-cycled. In addition, the optical properties of such an encoder system, wear, contamination, and other factors may contribute to errors in which the encoder does not perform as intended. Such performance problems may be manifested by the system missing an encoder “count” or registering extra or unexpected “counts” that cannot be identified with use of the primary encoder alone. To address such possibilities, a secondary encoder, such as a magnetic encoder, can be used in conjunction with such pump systems to monitor rotation of the rotationally driven element to verify that the primary encoder is tracking correctly by comparing the amount of rotation determined by the primary encoder to the amount detected by the secondary encoder. Systems incorporating such designs enable extremely low power operation while still guaranteeing the primary encoder maintains sufficient position information.
In one embodiment, a secondary encoder for monitoring performance of a primary encoder of an infusion pump can include a magnetic sensor and a magnet. The magnet can be disposed on the same rotationally driven element monitored by the primary encoder and the magnetic sensor, by sensing the magnet, can monitor the number of revolutions of the rotary element during various pump operations. The system can compare the detected number of revolutions to the number of revolutions detected by the primary encoder. If the number of revolutions detected by each encoder is the same, then no further action needs to be taken and the pump can proceed with normal pump operation. If the numbers are not the same, it may be indicative of an error in operation of the primary encoder.
In another embodiment, a secondary encoder for monitoring performance of a primary encoder of an infusion pump can include a magnetic sensor and a magnet. The magnet can be disposed on the same rotationally driven element monitored by the primary encoder and the magnetic sensor, by sensing the magnet, can monitor an amount of rotation of the rotary element during various pump operations. The system can compare the detected number of encoder counts (e.g., markings detected by the primary encoder) to an expected number or range of numbers of encoder counts based on the amount of rotation detected by the magnetic encoder. If the number of counts is the expected number or within the expected range, then no further action needs to be taken and the pump can proceed with normal pump operation. If the numbers are not the same or within an expected range, it may be indicative of an error in operation of the primary encoder.
In one embodiment, an ambulatory infusion pump system includes a reservoir configured to contain a medicament including a plunger at a proximal end of the reservoir and an outlet port at a distal end of the reservoir, a pushrod, and a motor configured to cause linear motion of the pushrod. The pump can further include an optical encoder configured to monitor a linear position of the pushrod. A processor can be configured to control the motor and pushrod to cause delivery of medicament from the reservoir by causing the pushrod to contact and move the reservoir plunger. The processor can command the motor to actuate to deliver medicament from the reservoir by advancing the pushrod from a first linear position to a second linear position and monitor a move completion time for the pushrod to advance from the first linear position to the second linear position. The processor can compare the move completion time to an expected move completion time and notify a user of an error if the monitored move completion time is longer than the expected move completion time. In one or more embodiments, the optical encoder monitors the linear position of the pushrod by monitoring markings on a rotating drive tube that causes linear motion of the pushrod when it is rotated.
In one embodiment an ambulatory infusion pump system includes a reservoir configured to contain a medicament including a plunger at a proximal end of the reservoir and an outlet port at a distal end of the reservoir, a pushrod, a drive tube including a plurality of markings configured to cause linear motion of the pushrod when the drive tube is rotated and a motor configured to cause the drive tube to rotate to cause linear motion of the pushrod to contact and move the plunger to cause medicament to flow from the reservoir out of the outlet port to a patient. The system can further include an optical encoder configured to monitor a linear position of the pushrod by sensing the markings on the drive tube when the drive tube is rotated. A magnetic sensor can further be included and be configured to monitor rotation of the drive tube by sensing a magnet disposed on the drive tube when the drive tube is rotated. In one or more embodiments, performance of the optical encoder can be monitored by comparing the rotation of the drive tube as monitored by the optical encoder with the rotation as monitored by the magnetic sensor.
The above summary is not intended to describe each illustrated embodiment or every implementation of the subject matter hereof. The figures and the detailed description that follow more particularly exemplify various embodiments.
Subject matter hereof may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying figures, in which:
While various embodiments are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the claimed inventions to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the subject matter as defined by the claims.
In one embodiment, pump 102 includes a processor that controls operations of the pump and, in some embodiments, may communicate in either one-way or two-way modes to, e.g., receive commands and/or other signals, including data, from a separate device and/or, e.g., to send signals, including data, to a separate device. Such a separate device can include, for example, a dedicated remote control or a smartphone or other consumer electronic device executing an application configured to enable the device to transmit operating commands to the processor of pump 102. In some embodiments, processor can also transmit information to one or more separate devices, such as information pertaining to device parameters, alarms, reminders, pump status, etc. Such communications between (and among) the one or more devices and pump may be one-way or two-way for, e.g., effective transfer of data among the devices and the pump, control of pump operations, updating software on the devices and/or pump, and allowing pump-related data to be viewed on the devices and/or pump.
The primary elements of the motor assembly utilized to translate the rotational motion of a ceramic drive disk 214 induced by the motors 201 into linear motion include a drive tube 202, a lead screw 204 and a drive nut or pushrod 206. As can be most clearly seen in
In one embodiment, operation of the unit is accomplished by energizing the piezoelectric motors with an electrical drive signal to cause them to oscillate against the ceramic drive disk 214. This oscillation induces rotational motion of the ceramic drive disk 214. Rotational motion of the ceramic drive disk 214 causes the drive tube 202 and the lead screw 204 to rotate. The intermeshing threaded exterior portion 212 of the lead screw 204 and interior threaded portion 217 of the pushrod 206 along with the non-circular perimeter 216 of the pushrod 206 that is constrained from rotating by the guide bushing 218 cause this rotational motion to be converted into linear motion of the pushrod 206. When the drive mechanism 122 is attached to a cartridge containing medicament, such as cartridge 116, the linear motion of the pushrod 206 causes the drive tip 234 of the pushrod to advance a syringe in the cartridge to cause medicament to be dispensed from the cartridge. Further details regarding such a drive system can be found in U.S. Patent Publication No. 2017/0049957, previously incorporated herein by reference.
An additional feature that can be utilized by a drive mechanism according to embodiments of the present invention is an optical encoder system. Referring to
In one embodiment, the optical encoder system can monitor three output channels that are indicated by the markings 242 on the drive tube 202. These can include, for example, an A channel, a B channel and an index channel. Monitoring of the A channel and the B channel can be used by the system to determine the rotational position, speed, and direction of rotation of the drive tube.
Monitoring of the index channel can serve a number of purposes. For example, the index channel can be configured such that one index channel pulse is expected for a set number of A and B pulses. If that index channel pulse is not detected after the set number of A and B pulses, it can be inferred that the encoder system may not be operating properly, and one or more signals can be sent to a processor or other device to disable the drive system, send a warning or other message to a user, etc. Similarly, this configuration can be used to determine if the drive tube moved when the encoder system was not turned on. Generally speaking, this may occur because, in an effort to save battery power, the encoder is only turned on right before a motor move and then turned off shortly after the move is complete. As such, if some fault (e.g., hardware fault, cosmic ray, etc.) causes the drive tube to rotate when the encoder is power off, it cannot be determined from monitoring only the A and B channels. Comparing the index pulse signal to the A and B signals enables detection of such fault conditions. This configuration can further be used to determine if the A and B channels are operating as expected; if so, one index pulse should be received for each set number of A and B pulses as noted above. In the described optical encoder system, the markings 242 that are monitored are provided on a component of the system, drive tube 202, that otherwise serves an additional functional purpose (rotating the lead screw).
Systems as described herein generally include a normal amount of “slippage” during normal load conditions. Slippage occurs between the drive tip and the drive disk and refers to kinetic energy from the motion of the drive tip that is converted to heat instead of motion of the drive disk. This includes startup slippage due to inertia and steady state slippage due to rotational resistance from a variety of sources (e.g., ball bearing friction, bushing friction, and axial load on the drive nut from the cartridge plunger friction). At startup (e.g., when the motor is first energized), the drive tip oscillates at a certain speed and this movement reaches steady state almost instantaneously, but the inertia of the drive disk and drive tube assembly prevents the drive disk-drive tube assembly from matching that very high acceleration, which results in the startup slippage. During steady state conditions (constant rotational speed) there is slippage due to the fact that there is an imperfect frictional connection between the drive tip and the drive disk and as the load increases, slippage increases and more of the kinetic energy from the motion of the drive tip is converted to heat instead of motion of the drive disk.
Encoder system can also be used indirectly to, e.g., monitor pressure in the pump. In one embodiment, as pressure in cartridge 116 increases, more force is required to advance the syringe and push rod 206, and accordingly the torque required to rotate the lead screw 204 increases. In turn, the amount of slippage, as described above, between the piezoelectric motors 201 and the drive disk 214 increases to greater than the normal amount due to this increased torque level. This increase in slippage causes a rotational displacement of the marked drive tube 202 and lead screw 204 of a given amount to take a longer amount of time. By monitoring the time required for a given rotational displacement to occur, high force and low force conditions on the cartridge syringe and push rod 206 due to pressure in the pump can be determined. This enables one or more pump-related conditions to be detected, including the presence or absence of occlusion, the presence or absence of a cartridge, general performance and health of the drive system of the pump, etc. The pump can include an internal timer that the processor uses to determine the move completion time. Monitoring of pump conditions in this manner can be done by the processor within the pump described above. Alternatively, a separate device, such as a dedicated remote control or a smartphone, can receive data relating to the encoder from the pump processor, monitor the data, and make determinations relating to pump conditions. Such data may also be recorded into memory of the pump and/or a separate device and analyzed further using diagnostic tools such as may reside on a server, diagnostic and/or repair equipment, etc.
By way of example only (as such times can vary significantly depending on a particular design configuration), typical move completion times for the drive tube and lead screw to rotate a given distance during normal system operations (when the pushrod is advancing the cartridge syringe to dispense medicament) may be in a range of about 20 milliseconds to about 40 milliseconds. When move completion times for the given distance are longer than about 40 milliseconds, this may indicate there is additional slippage in the system because not all of the piezoelectric energy is being converted to rotational motion of the drive disk and drive tube—and corresponding linear motion of the pushrod. The processor then can infer that one or more of a number of conditions in the system, such as those discussed above, may be present. Similarly, there may be situations where no rotational movement is detected. Such a situation may indicate that enough of the piezoelectric energy is being lost in slippage such that the pushrod has not linearly advanced at all in the time period observed/monitored. Thus, while the system is generally referred to herein as detecting “move completion time”, it should be understood that in circumstances where no movement is detected, there is no actual movement and the move completion time instead refers to reaching a threshold period of time wherein the lack of movement indicates a system condition.
When no rotational movement is detected, meaning that an insufficient amount of piezoelectric energy is being converted to effectuate the desired degree of rotational movement of the drive disk, the processor can infer that one or more of several conditions may be present in the system. Such conditions include, for example, that the drive system is stuck, that the cartridge is empty and/or that the pushrod has reached its full travel state. The condition of the system can be determined by the processor based on the position of the pushrod relative to the fully retracted and/or full extended states of the pushrod as indicated by the encoder system and the amount of medicament that the system has calculated as is remaining in the reservoir. If the pushrod is in its fully extended state, then no further rotational movement indicates that the pushrod has reached its fully extended travel state. If the pushrod is not fully extended, the condition of the system can be determined based on the amount of medicament that the processor has tracked as remaining in the reservoir. If the processor has determined that only a small amount of medicament is remaining in the reservoir, such as, for example, 5 to 10 units of medicament or less, but there is no rotational motion of the drive tube when the motor is actuated, the system can infer that the cartridge is empty. If there is no rotational motion but the processor has determined that a significant amount of medicament, such as, for example 100 units of medicament, is remaining in the cartridge, the processor can infer that the drive system is stuck.
When the drive tube is rotating such that the pushrod is moving linearly upon motor actuation, but the move completion time is longer than expected, this may indicate that a high pressure condition exists in the system, such as an occlusion in the fluid line. For example, if there is an expected move completion time of between about 20 ms to about 40 ms, a move completion time of about 50 ms can cause the processor to infer that there is an occlusion, and any number of actions optionally may be taken as a result thereof and as described below.
The time it takes for a given rotational displacement to occur can also be monitored to detect low pressure conditions. As discussed above, rotation of the lead screw 204 causes linear motion of the pushrod 206 such that a drive tip 234 of the pushrod contacts and advances a syringe in the cartridge to cause medicament to be dispensed from the cartridge 116. There is accordingly a level of force exerted on the pushrod from the cartridge syringe during normal system operations. If the pushrod is not in contact with the syringe, this force is not present which will lead to lower move completion times. For example, if typical move completion times when the pump is dispensing medicament are between about 20 and about 40 milliseconds, move completion times less than about 20 ms can indicate that the pushrod is not in contact with the syringe. This could indicate that the cartridge is not present (which would be visually apparent) and can also be used during priming of the cartridge during initial use following a cartridge fill to determine when the pushrod has contacted the syringe plunger. The ability to determine that the pushrod is not in contact with the cartridge syringe also provides an additional safety feature because it indicates that the pump may not be dispensing medicament when the motors are actuated.
The system can take various actions based on detected system conditions. The system can provide an alarm or alert related to a detected condition on a user interface of the pump and/or on a user interface of a remote control device, such as a dedicated remote control or a smartphone. Such alarms or alerts may also include an auditory and/or vibratory alert. For example, if the system has determined that an occlusion is present, an occlusion alarm can be issued. Such an alert may notify the user that an occlusion has been detected and instruct the user to clear the occlusion. In some embodiments, the user can enter a troubleshooting mode through the alarm that provides instructions and/or suggestions for clearing the occlusion (or other condition). The user may be able to acknowledge and clear the alarm. If the occlusion was not properly remedied prior to clearing the alarm, the system will again detect the occlusion and provide another alarm. A corresponding alert or alarm can be provided for other detected system conditions in a similar manner, such as the cartridge being empty or missing, the drive system being stuck, and the pushrod having reached the end of its travel. In some embodiments, when the occlusion or other system condition alarm is issued, the system also automatically ceases medicament delivery until the alarm is cleared.
Still referring to
The system can be adjusted to modify a sensitivity setting for the various alerts and alarms described herein in various embodiments of the invention. As discussed above, typical move completion times in the system may be in the range of about 20 to about 40 milliseconds. The alarm sensitivity can be adjusted by changing the amount of time a move must take before an alarm is triggered. For example, in one embodiment as discussed above an alarm is triggered when a move completion time is 50 milliseconds or longer. To increase the alarm sensitivity, the alarm time threshold could be decreased to 40 milliseconds. Similarly, the alarm sensitivity can be decreased by increasing the alarm time threshold, such as, for example, to about 60 milliseconds. In addition, detection thresholds could be set based on the characteristics of a given drive system to account for system-to-system variability such that each system could have a different move duration threshold to decrease the variation across systems in the amount of missed medicament when an occlusion is detected.
As disclosed in U.S. Patent Publication No. 2017/0049957, in some embodiments an ambulatory infusion pump can include a second encoder 241 in addition to primary encoder 240. In one embodiment, the second encoder 241 can be positioned as shown in
In some embodiments, second encoder can be a magnetic sensor used to monitor the primary encoder performance by providing input to an algorithm for monitoring the performance of the primary encoder. Referring to
Because the primary encoder 240 operates relative to the markings 242, it can drift slightly when power off or power cycled to reduce the power consumption of pump. Encoder 240 can also experience other problems—as previously described—each of which could contribute to one or more performance errors and/or other problems. Therefore, as noted above, in various embodiments, secondary encoder 241 can be used to monitor performance of the primary encoder 240 to ensure that the primary encoder is properly tracking the rotational position and speed of the drive tube 202. Such a system is useful in detecting primary encoder system failures in order to prevent such failures from leading to delivery errors, which can lead to serious medical consequences for patients. Use of a magnetic encoder system as described herein therefore enables encoder monitoring with extremely low power operation.
In one embodiment, magnetic sensor 241 can monitor primary encoder 240 performance during cartridge 116 changing, pump priming or other operations that involve use of the motors 201 to effect rewinding or extending of the leadscrew 204. The magnetic sensor 241, by sensing the magnet 243, can monitor the number of revolutions of the drive tube 202 during one or more of the above procedures and compare the detected number of revolutions to the number of revolutions detected by the primary encoder 240. If the number of revolutions detected by each encoder is the same, then no further action needs to be taken and the pump can proceed with normal pump operation. If the numbers are not the same, it may be indicative of an error in operation of the primary encoder and an alarm or alert can be issued to notify the user of the error.
If an error is detected in operation of the primary encoder, one or more signals may be sent to a processor to disable the drive system. The user may optionally be notified, e.g., that the drive system has been automatically disabled, to request a user confirmation to disable the drive system, etc. In some embodiments, the system may automatically, or by user prompt, run one or more self-tests to confirm the error. Such a self-test may involve, e.g., retracting the lead screw, operating the motors and comparing secondary magnetic and primary optical encoder readings and/or confirming that the magnetic detection(s) were from the magnet and not a false detections that could be triggered by, e.g., an external force not related to the drive system. In some embodiments, if the error is confirmed, if an error is detected in embodiments that do not automatically self-test to confirm the error, the user can be instructed to return the pump to the manufacturer and/or contact the manufacturer to, e.g., obtain a replacement.
Magnetic sensor 241 can also be utilized to monitor primary encoder 240 performance during normal pumping operations, e.g., when delivering medicament to a patient with the pump. As discussed above, primary encoder 240 monitors a plurality of markings 242, or counts, on the drive tube 202 during device operation. During routine medicament delivery, the number of monitored counts in a given time period corresponds with an amount of medicament delivered over the time period. It is therefore important that the number of encoder counts is properly and accurately measured by the primary encoder. When magnetic sensor 241 is triggered, the number of encoder counts as measured by primary encoder 240 can be compared to a target number or range of encoder counts that are expected to have occurred. For example, in the embodiment employing one magnet 243 on drive tube 202, the drive tube 202 will have undergone one complete revolution each time magnetic sensor 241 is triggered. The number of encoder counts measured by the primary encoder can therefore be compared to an expected number or range of encoder counts and if the number is the same as the expected number or within the expected range, pumping operations can continue uninterrupted. If not, the user can be notified of the error and/or the drive system disabled as described above. Such an error may occur due to the primary encoder being turned off and on within a given revolution such that it is possible for counts to be missed or for extra counts to occur.
In addition to or alternatively to monitoring and comparing the number of discrete encoder counts, the magnetic sensor 241 can be used to determine whether the number of complete revolutions of the drive tube 202 measured by the primary encoder 241 during normal pumping operations is accurate. The drive tube 202 in a pump as described herein may undergo a number of complete revolutions to deliver the medicament contained in a given cartridge. A further check on the performance of the primary encoder can therefore be to compare the number of complete revolutions of drive tube 202 as measured by the primary encoder to the number of revolutions determined by the magnetic sensor 241. For example, in the embodiment where there is one magnet 243 that therefore triggers the magnetic sensor 241 once a at a single absolute position each revolution, the number of times that the magnetic sensor has been triggered can be compared to the number of revolutions measured by the primary encoder 243. In embodiments employing more than one magnetic sensor a different number of magnetic sensor triggers will equal a complete revolution to be compared to the primary encoder, or a smaller revolution amount can be monitored and compared, such as, for example, half revolutions. If the number of revolutions determined by the primary encoder and the magnetic encoder is the same, pumping operations can continue uninterrupted. If not, the user can be notified of the error and/or the drive system disabled as described above.
A magnetic encoder can further be used to monitor primary encoder 240 performance during a user-initiated or automatic self-test of the system. No medicament is delivered by the system as the test is conducted solely for the purpose of testing the performance of the primary encoder, regardless of the presence or absence of an internal and/or user-facing (e.g., graphical user interface on the pump or remote device, via vibratory and/or audible means, etc.) indication of an error or other prompting. Such a test can otherwise be conducted similarly to the encoder monitoring described above during normal pump operations, with the number of counts and/or revolutions determined by the primary encoder 240 compared to a number or range of expected counts and/or revolutions as monitored by the magnetic encoder system.
Referring now to
Also incorporated herein by reference in their entirety are commonly owned U.S. Pat. Nos. 8,287,495; 8,408,421 8,448,824; 8,573,027; 8,650,937; 8,986,523; 9,173,998; 9,180,242; 9,180,243; 9,238,100; 9,242,043; 9,335,910; 9,381,271; 9,421,329; 9,486,171; 9,486,571; 9,492,608; 9,503,526; 9,555,186; 9,565,718; 9,603,995; 9,669,160; 9,715,327; 9,737,656; 9,750,871; 9,867,937; 9,867,953; 9,940,441; 9,993,595; 10,016,561 and 10,201,656. commonly owned U.S. Patent Publication Nos. 2009/0287180; 2012/0123230; 2013/0053816; 2014/0276419; 2014/0276420; 2014/0276423; 2014/0276569; 2014/0276570; 2015/0182693; 2016/0082188; 2017/0049957; 2017/0142658; 2017/0182248; 2017/0250971; 2018/0021514; 2018/0071454 and 2018/0193555 commonly owned U.S. patent application Ser. No. 14/707,851; and commonly owned U.S. Provisional Application Ser. Nos. 61/911,576; 61/920,902; 61/920,914; 61/920,940; 62/139,275; 62/352,164; 62/545,228; 62/655,516; 62/677,433; 62/743,901; 62/784,939; and 62/784,949.
Further incorporated by reference herein in their entirety are U.S. Pat. Nos. 8,601,465; 8,502,662; 8,452,953; 8,451,230; 8,449,523; 8,444,595; 8,343,092; 8,285,328; 8,126,728; 8,117,481; 8,095,123; 7,999,674; 7,819,843; 7,782,192; 7,109,878; 6,997,920; 6,979,326; 6,936,029; 6,872,200; 6,813,519; 6,641,533; 6,554,798; 6,551,276; 6,295,506; and 5,665,065.
Various embodiments of systems, devices, and methods have been described herein. These embodiments are given only by way of example and are not intended to limit the scope of the claimed inventions. It should be appreciated, moreover, that the various features of the embodiments that have been described may be combined in various ways to produce numerous additional embodiments. Moreover, while various materials, dimensions, shapes, configurations and locations, etc. have been described for use with disclosed embodiments, others besides those disclosed may be utilized without exceeding the scope of the claimed inventions.
Persons of ordinary skill in the relevant arts will recognize that the subject matter hereof may comprise fewer features than illustrated in any individual embodiment described above. The embodiments described herein are not meant to be an exhaustive presentation of the ways in which the various features of the subject matter hereof may be combined. Accordingly, the embodiments are not mutually exclusive combinations of features; rather, the various embodiments can comprise a combination of different individual features selected from different individual embodiments, as understood by persons of ordinary skill in the art. Moreover, elements described with respect to one embodiment can be implemented in other embodiments even when not described in such embodiments unless otherwise noted.
Although a dependent claim may refer in the claims to a specific combination with one or more other claims, other embodiments can also include a combination of the dependent claim with the subject matter of each other dependent claim or a combination of one or more features with other dependent or independent claims. Such combinations are proposed herein unless it is stated that a specific combination is not intended.
Any incorporation by reference of documents above is limited such that no subject matter is incorporated that is contrary to the explicit disclosure herein. Any incorporation by reference of documents above is further limited such that no claims included in the documents are incorporated by reference herein. Any incorporation by reference of documents above is yet further limited such that any definitions provided in the documents are not incorporated by reference herein unless expressly included herein.
For purposes of interpreting the claims, it is expressly intended that the provisions of 35 U.S.C. § 112(f) are not to be invoked unless the specific terms “means for” or “step for” are recited in a claim.
The present application claims the benefit of U.S. Provisional Application No. 62/626,430 filed Feb. 5, 2018 and U.S. Provisional Application No. 62/632,294 filed Feb. 19, 2018, each of which is hereby incorporated herein in its entirety by reference.
Number | Name | Date | Kind |
---|---|---|---|
4019073 | Vishnevsky et al. | Apr 1977 | A |
4741736 | Brown | May 1988 | A |
5097122 | Colman et al. | Mar 1992 | A |
5236416 | McDaniel | Aug 1993 | A |
5795327 | Wilson et al. | Aug 1998 | A |
6120460 | Abreu | Sep 2000 | A |
6158431 | Poole | Dec 2000 | A |
6362591 | Moberg | Mar 2002 | B1 |
6413254 | Hissong et al. | Jul 2002 | B1 |
6423035 | Das et al. | Jul 2002 | B1 |
6468242 | Wilson et al. | Oct 2002 | B1 |
6485465 | Moberg et al. | Nov 2002 | B2 |
6555986 | Moberg | Apr 2003 | B2 |
6659980 | Moberg et al. | Dec 2003 | B2 |
6669669 | Flaherty et al. | Dec 2003 | B2 |
6749587 | Flaherty | Jun 2004 | B2 |
6885881 | Leonhardt | Apr 2005 | B2 |
6913933 | Jacobs et al. | Jul 2005 | B2 |
6918542 | Silverbrook et al. | Jul 2005 | B2 |
6940209 | Henderson | Sep 2005 | B2 |
7064472 | Pelrine et al. | Jun 2006 | B2 |
7066909 | Peter et al. | Jun 2006 | B1 |
7073713 | Silverbrook et al. | Jul 2006 | B2 |
7083108 | Silverbrook et al. | Aug 2006 | B2 |
7092011 | Silverbrook et al. | Aug 2006 | B2 |
7097104 | Silverbrook et al. | Aug 2006 | B2 |
7107706 | Bailey, Sr. et al. | Sep 2006 | B1 |
7141812 | Appleby et al. | Nov 2006 | B2 |
7144384 | Gorman et al. | Dec 2006 | B2 |
7170214 | Henderson et al. | Jan 2007 | B2 |
7187404 | Silverbrook et al. | Mar 2007 | B2 |
7193521 | Moberg et al. | Mar 2007 | B2 |
7201319 | Silverbrook et al. | Apr 2007 | B2 |
7234645 | Silverbrook et al. | Jun 2007 | B2 |
7256824 | Silverbrook | Aug 2007 | B2 |
7289142 | Silverbrook | Oct 2007 | B2 |
7309943 | Henderson et al. | Dec 2007 | B2 |
7316700 | Alden et al. | Jan 2008 | B2 |
7339306 | Henderson | Mar 2008 | B2 |
7362971 | Silverbrook et al. | Apr 2008 | B2 |
7373083 | Silverbrook et al. | May 2008 | B2 |
7377706 | Silverbrook et al. | May 2008 | B2 |
7394182 | Pelrine et al. | Jul 2008 | B2 |
7411204 | Appleby et al. | Aug 2008 | B2 |
7460152 | Silverbrook et al. | Dec 2008 | B2 |
7464580 | Zeng et al. | Dec 2008 | B2 |
7475825 | Silverbrook et al. | Jan 2009 | B2 |
7483050 | Silverbrook et al. | Jan 2009 | B2 |
7497827 | Brister | Mar 2009 | B2 |
7517332 | Tonelli et al. | Apr 2009 | B2 |
7524045 | Silverbrook et al. | Apr 2009 | B2 |
7534226 | Mernoe et al. | May 2009 | B2 |
7551202 | Silverbrook | Jun 2009 | B2 |
7582063 | Wurster et al. | Sep 2009 | B2 |
7621893 | Moberg et al. | Nov 2009 | B2 |
7654127 | Krulevitch et al. | Feb 2010 | B2 |
7704227 | Moberg et al. | Apr 2010 | B2 |
7708717 | Estes et al. | May 2010 | B2 |
7713574 | Brister et al. | May 2010 | B2 |
7714889 | Silverbrook | May 2010 | B2 |
7736344 | Moberg et al. | Jun 2010 | B2 |
7744589 | Mounce et al. | Jun 2010 | B2 |
7766873 | Moberg et al. | Aug 2010 | B2 |
7774145 | Brauker et al. | Aug 2010 | B2 |
7776030 | Estes et al. | Aug 2010 | B2 |
7786648 | Xu et al. | Aug 2010 | B2 |
7794427 | Estes et al. | Sep 2010 | B2 |
7794428 | Estes et al. | Sep 2010 | B2 |
7806868 | De Polo et al. | Oct 2010 | B2 |
7887512 | Estes et al. | Feb 2011 | B2 |
7892206 | Moberg et al. | Feb 2011 | B2 |
7905868 | Moberg et al. | Mar 2011 | B2 |
7922458 | Rush | Apr 2011 | B2 |
7935104 | Yodfat et al. | May 2011 | B2 |
7938803 | Mernoe et al. | May 2011 | B2 |
7944366 | Krulevitch et al. | May 2011 | B2 |
7955295 | Lee et al. | Jun 2011 | B2 |
7963945 | Miller et al. | Jun 2011 | B2 |
7981084 | Estes et al. | Jul 2011 | B2 |
7988660 | Byland et al. | Aug 2011 | B2 |
7993109 | Rush et al. | Aug 2011 | B2 |
7998110 | Leung et al. | Aug 2011 | B2 |
7998111 | Moberg et al. | Aug 2011 | B2 |
8062257 | Moberg et al. | Nov 2011 | B2 |
8065096 | Moberg et al. | Nov 2011 | B2 |
8100852 | Moberg et al. | Jan 2012 | B2 |
8105279 | Mernoe et al. | Jan 2012 | B2 |
8182447 | Moberg et al. | May 2012 | B2 |
8187228 | Bikovsky | May 2012 | B2 |
8217533 | Jones et al. | Jul 2012 | B2 |
8267893 | Moberg et al. | Sep 2012 | B2 |
8282601 | Mernoe et al. | Oct 2012 | B2 |
8287495 | Michaud et al. | Oct 2012 | B2 |
8298184 | Diperna et al. | Oct 2012 | B2 |
8299733 | Sattler et al. | Oct 2012 | B2 |
8304960 | Sattler et al. | Nov 2012 | B2 |
8323188 | Tran | Dec 2012 | B2 |
8382703 | Abdelaal | Feb 2013 | B1 |
8414563 | Kamen et al. | Apr 2013 | B2 |
8450905 | Guidarelli et al. | May 2013 | B2 |
8466637 | Guidarelli et al. | Jun 2013 | B2 |
8517991 | Clemente | Aug 2013 | B2 |
8562590 | Yodfat et al. | Oct 2013 | B2 |
8573027 | Rosinko et al. | Nov 2013 | B2 |
8641671 | Michaud et al. | Feb 2014 | B2 |
8758323 | Michaud et al. | Jun 2014 | B2 |
8926561 | Verhoef et al. | Jan 2015 | B2 |
8986253 | Diperna | Mar 2015 | B2 |
9180243 | Michaud | Nov 2015 | B2 |
9211377 | Diperna et al. | Dec 2015 | B2 |
9362851 | Xu et al. | Jun 2016 | B2 |
9421329 | Kruse | Aug 2016 | B2 |
9555186 | Kruse | Jan 2017 | B2 |
9675756 | Kamen | Jun 2017 | B2 |
9962486 | Rosinko et al. | May 2018 | B2 |
9993595 | Michaud et al. | Jun 2018 | B2 |
10010674 | Rosinko et al. | Jul 2018 | B2 |
10279106 | Cook et al. | May 2019 | B1 |
10279107 | Michaud | May 2019 | B2 |
10357603 | Michaud et al. | Jul 2019 | B2 |
10850032 | Steck et al. | Dec 2020 | B2 |
20030060768 | Kiyatake et al. | Mar 2003 | A1 |
20030163090 | Blomquist et al. | Aug 2003 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040220551 | Flaherty et al. | Nov 2004 | A1 |
20050010980 | Inoue et al. | Jan 2005 | P1 |
20050020980 | Inoue et al. | Jan 2005 | A1 |
20050177111 | Ozeri et al. | Aug 2005 | A1 |
20060049720 | Henderson et al. | Mar 2006 | A1 |
20070062250 | Krulevitch et al. | Mar 2007 | A1 |
20070093753 | Krulevitch | Apr 2007 | A1 |
20070149926 | Moberg et al. | Jun 2007 | A1 |
20070156092 | Estes et al. | Jul 2007 | A1 |
20070167905 | Estes et al. | Jul 2007 | A1 |
20070173762 | Estes et al. | Jul 2007 | A1 |
20070270750 | Dacquay | Nov 2007 | A1 |
20080045902 | Estes et al. | Feb 2008 | A1 |
20080045903 | Estes et al. | Feb 2008 | A1 |
20080045904 | Estes et al. | Feb 2008 | A1 |
20080045931 | Estes et al. | Feb 2008 | A1 |
20080051697 | Mounce et al. | Feb 2008 | A1 |
20080051698 | Mounce et al. | Feb 2008 | A1 |
20080051709 | Mounce et al. | Feb 2008 | A1 |
20080051711 | Mounce | Feb 2008 | A1 |
20080051716 | Stutz | Feb 2008 | A1 |
20080051727 | Moberg et al. | Feb 2008 | A1 |
20080097291 | Hanson et al. | Apr 2008 | A1 |
20080097375 | Bikovsky | Apr 2008 | A1 |
20080097381 | Moberg et al. | Apr 2008 | A1 |
20080125700 | Moberg et al. | May 2008 | A1 |
20080215035 | Yodfat et al. | Sep 2008 | A1 |
20080221523 | Moberg et al. | Sep 2008 | A1 |
20090036870 | Mounce et al. | Feb 2009 | A1 |
20090124994 | Roe | May 2009 | A1 |
20090157003 | Jones | Jun 2009 | A1 |
20090192724 | Brauker et al. | Jul 2009 | A1 |
20090270811 | Mounce et al. | Oct 2009 | A1 |
20100037680 | Moberg et al. | Feb 2010 | A1 |
20100078017 | Andrieux | Apr 2010 | A1 |
20100121169 | Petisce et al. | May 2010 | A1 |
20100152674 | Kavazov et al. | Jun 2010 | A1 |
20100179402 | Goode, Jr. et al. | Jul 2010 | A1 |
20100185142 | Kamen et al. | Jul 2010 | A1 |
20100185175 | Kamen et al. | Jul 2010 | A1 |
20100198183 | Lanigan et al. | Aug 2010 | A1 |
20100211003 | Sundar | Aug 2010 | A1 |
20100217192 | Moberg et al. | Aug 2010 | A1 |
20100217193 | Moberg et al. | Aug 2010 | A1 |
20100249706 | Clemente | Sep 2010 | A1 |
20100324398 | Tzyy-Ping | Dec 2010 | A1 |
20110054390 | Searle et al. | Mar 2011 | A1 |
20110092948 | Shachar et al. | Apr 2011 | A1 |
20110144586 | Michaud et al. | Jun 2011 | A1 |
20110144616 | Michaud et al. | Jun 2011 | A1 |
20110152770 | Diperna et al. | Jun 2011 | A1 |
20110152824 | Diperna et al. | Jun 2011 | A1 |
20110152827 | Wiegel et al. | Jun 2011 | A1 |
20110160654 | Hanson et al. | Jun 2011 | A1 |
20110166544 | Verhoef et al. | Jul 2011 | A1 |
20110190614 | Brister et al. | Aug 2011 | A1 |
20110190694 | Lanier, Jr. et al. | Aug 2011 | A1 |
20110213329 | Yodfat et al. | Sep 2011 | A1 |
20110257895 | Brauker et al. | Oct 2011 | A1 |
20120029433 | Michaud et al. | Feb 2012 | A1 |
20120029468 | Diperna | Feb 2012 | A1 |
20120030610 | Diperna et al. | Feb 2012 | A1 |
20120041387 | Bruggemann | Feb 2012 | A1 |
20120078216 | Smith et al. | Mar 2012 | A1 |
20120096954 | Vazquez et al. | Apr 2012 | A1 |
20120172817 | Brueggemann et al. | Jul 2012 | A1 |
20120192951 | Yodfat et al. | Aug 2012 | A1 |
20120259282 | Alderete, Jr. | Oct 2012 | A1 |
20130053816 | Diperna et al. | Feb 2013 | A1 |
20130150766 | Olde | Jun 2013 | A1 |
20130204542 | Olde | Aug 2013 | A1 |
20130324928 | Kruse | Dec 2013 | A1 |
20130331790 | Brown et al. | Dec 2013 | A1 |
20140039392 | Geipel et al. | Feb 2014 | A1 |
20140054883 | Lanigan et al. | Feb 2014 | A1 |
20140276423 | Lecanu-Fayet | Sep 2014 | A1 |
20150174320 | Grant | Jun 2015 | A1 |
20150202375 | Schabbach | Jul 2015 | A1 |
20160051758 | Rosinko et al. | Feb 2016 | A1 |
20160082186 | Rosinko et al. | Mar 2016 | A1 |
20160136357 | Yang | May 2016 | A1 |
20160157759 | Yang | Jun 2016 | A1 |
20160157765 | Zhu | Jun 2016 | A1 |
20160158436 | Yang | Jun 2016 | A1 |
20160199572 | Yang | Jul 2016 | A1 |
20160339172 | Michaud et al. | Nov 2016 | A1 |
20170049957 | Michaud | Feb 2017 | A1 |
20170056581 | Deak et al. | Mar 2017 | A1 |
20180071454 | Betts et al. | Mar 2018 | A1 |
20180264189 | Michaud et al. | Sep 2018 | A1 |
20180333543 | Diaz | Nov 2018 | A1 |
20190255248 | Michaud | Aug 2019 | A1 |
20190321546 | Michaud et al. | Oct 2019 | A1 |
Number | Date | Country |
---|---|---|
2930776 | May 2018 | CA |
1097632 | Jan 1995 | CN |
1611001 | Apr 2005 | CN |
101189431 | May 2008 | CN |
101563120 | Oct 2009 | CN |
103228303 | Jul 2013 | CN |
101745163 | Dec 2013 | CN |
103768679 | May 2014 | CN |
102015104786 | Sep 2016 | DE |
2420274 | Feb 2012 | EP |
2510960 | Oct 2012 | EP |
WO-0228532 | Apr 2002 | WO |
WO-2008024808 | Feb 2008 | WO |
WO-2008024812 | Feb 2008 | WO |
WO-2009013736 | Jan 2009 | WO |
WO-2009016636 | Feb 2009 | WO |
WO-2010096449 | Aug 2010 | WO |
WO 2016061194 | Apr 2016 | WO |
Entry |
---|
Extended European Search Report for Application No. 16837895.8, dated Nov. 7, 2018, 8 pages. |
International Preliminary Report on Patentability for Application No. PCT/US2016/047725, dated Mar. 1, 2018, 8 pages. |
International Search Report and Written Opinion for Application No. PCT/US2016/047725, dated Nov. 28, 2016, 12 pages. |
International Search Report and Written Opinion for Application No. PCT/US2019/016466, dated May 22, 2019, 13 pages. |
Application and File history for U.S. Appl. No. 16/403,016, filed May 3, 2019. Inventors: Michaud. |
Application and File history for U.S. Appl. No. 15/241,257, filed Aug. 19, 2016. Inventors: Michaud. |
Office Action dated Dec. 11, 2019 for Chinese Application No. 201680061057.X, 17 pages. |
Communication dated Feb. 17, 2020 for EP Application 16837895.8, 5 pages. |
Chinese Application No. 2019800235332, Search Report dated Oct. 24, 2021, 3 pages. |
Number | Date | Country | |
---|---|---|---|
20190240398 A1 | Aug 2019 | US |
Number | Date | Country | |
---|---|---|---|
62632294 | Feb 2018 | US | |
62626430 | Feb 2018 | US |